Izokibep

A Novel Interleukin-17A (IL-17A) Inhibitor Designed to Overcome the Limitations of Monoclonal Antibodies

Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. With high potency and small molecular size – about one tenth the size of a traditional monoclonal antibody – izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies otherwise require IV administration to achieve. We have hypothesized that these characteristics could lead to clinically meaningful and differentiated impact in multiple diseases.
A Novel Interleukin-17A (IL-17A) Inhibitor Designed to Overcome the Limitations of Monoclonal Antibodies

The Molecule

Unique, antibody mimetic designed to overcome limitations of monoclonal antibodies through enhanced potency, improved tissue penetration and extended plasma half-life

Loading...
About IL-17A
About IL-17A

IL-17A is one of the best-studied cytokines in immunology, especially around its involvement in inflammatory pathology. IL-17A has a major role in number inflammatory diseases and inhibiting IL-17A signaling has proven effective in treating a variety of diseases include plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Arrow white
About Enthesitis
About Enthesitis

Entheseal tissues anchor muscles to bone and bones to bone through tendons and ligaments. Given this role, enthesites have very high strength, are very dens...

Arrow white
Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Peter Taylor, MA, PhD, FRCP,FRCPE

Arrow white
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits

Philip Mease, MD, MACR

Arrow white
Indications

Hidradenitis Suppurativa

Psoriatic Arthritis

Axial Spondyloarthritis

Uveitis

Thyroid Eye Disease

Chronic Urticaria

Hidradenitis suppurativa (HS) is a very painful, lifelong, and recurring skin condition that causes abscesses and scarring 1,2. Areas often affected include the groin and genitals, the armpits, areas around the anus, and below the breasts1,2.

*Izokibep is not yet approved for use in any indication.
News Center

The Latest Company
Announcements and Resources